Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06496750 · ClinicalTrials.gov registry record · Phase 2
Ketamine for Methamphetamine Use Disorder
A Phase 2 study of Substance Use Disorders and Substance Use, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 4
- Study locations
NCT06496750: Recruiting Phase 2 study of Substance Use Disorders and Substance Use, sponsored by University of Texas Southwestern Medical Center.
NCT06496750 is a Phase 2 study of Substance Use Disorders and Substance Use that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 120 participants, below the 499-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (76% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06496750, a Phase 2 study of Substance Use Disorders and Substance Use, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study aims to determine whether treatment response with IV ketamine is superior to treatment response with IV midazolam in adults with moderate to severe MUD. The study design is a 12-week randomized, double-blind, controlled trial comparing intravenous (IV) ketamine against IV midazolam, delivered over six weeks in 120 adults with moderate to severe methamphetamine use disorder (MUD).
Primary Outcome
Defined as having at least three methamphetamine-negative urine samples out of four samples obtained during Weeks 3 and 4.
Conditions Studied
Interventions
- DRUG Ketamine Hydrochloride
- DRUG Midazolam Hydrochloride
Study Locations (4)
New Mexico
- Interdisciplinary Substance Use and Brain Injury Facility - Albuquerque
New York
- Addiction Institute of Mount Sinai - New York
South Carolina
- Prisma Health - Greenville
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-09-11 |
| Est. Completion | 2026-10-15 |
| Phase | Phase 2 |
What NCT06496750 shows while recruiting
NCT06496750 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 499-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (76% lower).
The record links to 3 conditions, with Substance Use Disorders appearing as the primary indexed condition, and to 2 interventions - of which Ketamine Hydrochloride is the first listed.
NCT06496750 reports a single indexed study location in New Mexico, New York, South Carolina.
Frequently Asked Questions
What is clinical trial NCT06496750 about?
NCT06496750 is a clinical study titled "Ketamine for Methamphetamine Use Disorder". This study aims to determine whether treatment response with IV ketamine is superior to treatment response with IV midazolam in adults with moderate to severe MUD. The study design is a 12-week randomized, double-blind, controlled trial comparing intravenous (IV) ketamine against IV midazolam, deli...
What is the current status of trial NCT06496750?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2024-09-11. Estimated completion is 2026-10-15.
What conditions does trial NCT06496750 study?
This clinical trial studies the following conditions: Substance Use Disorders, Substance Use, Methamphetamine Abuse.
What interventions are being tested in trial NCT06496750?
The interventions under investigation include: Ketamine Hydrochloride (DRUG), Midazolam Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT06496750?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06496750 being conducted?
This trial has 4 study locations across New Mexico, New York, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Use Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06496750's enrollment target sits among peer trials
120 45th of 93 higher than 45 of 93 other Substance Use Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Substance Use Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
RAE (Realize, Analyze, Engage)
COMPLETED · Phase 2
-
Supporting Treatment Access and Recovery Through Linkage and Support
RECRUITING · NA
-
Development OF A Novel Peer Recovery Supporter Training Platform
RECRUITING · NA
-
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
RECRUITING · NA
-
Testing Strategies to Improve Substance Misuse Prevention Research Use in State Policy Contexts
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI